These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8768271)

  • 61. The future of lipid-lowering therapy: the big picture.
    Kastelein JJ
    Neth J Med; 2003 May; 61(5 Suppl):35-9. PubMed ID: 12918548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
    Delahaye F; De Gevigney G
    Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of hyperlipidemia in cardiac transplant recipients.
    Bilchick KC; Henrikson CA; Skojec D; Kasper EK; Blumenthal RS
    Am Heart J; 2004 Aug; 148(2):200-10. PubMed ID: 15308989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HIV protease inhibitors and dyslipidemia.
    Clotet B; Negredo E
    AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
    Ballantyne CM; Bourge RC; Domalik LJ; Eisen HJ; Fishbein DP; Kubo SH; Lake KD; Radovancevic B; Taylor DO; Ventura HO; Yancy CW; Young JB
    Am J Cardiol; 1996 Sep; 78(5):532-5. PubMed ID: 8806337
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
    Shepherd J
    Eur Heart J; 1995 Jan; 16(1):5-13. PubMed ID: 7737222
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment of lipids. Implications for the general practitioner.
    Simons LA
    Aust Fam Physician; 1996 Jul; 25(7):1053-9. PubMed ID: 8768271
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Statins and fibrates in the management of diabetic dyslipidemia.
    Durrington P
    Diabet Med; 1997 Jul; 14(7):513-6. PubMed ID: 9223386
    [No Abstract]   [Full Text] [Related]  

  • 74. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.